Hua Medicine

Hua Medicine is a unique exception among China's cancer enterprises, producing medications for diabetes and central nervous system illnesses. Hua developed a potential first-in-class oral diabetes medication that targets glucokinase, a glucose sensor found in the pancreas and liver.

Activating faulty glucokinase to restore normal regulation of glucose balance is one of the primary prospects for combating Type 2 diabetes, but despite encouraging early results, several Big Pharma companies have attempted and failed in their attempts.

Hua announced in November that the phase 3 Seed trial of dorzagliatin monotherapy had met its primary goal. It was discovered that the medicine reduced new patients' HbA1c blood sugar levels by an average of 1.07% from baseline of 8.35% after 24 weeks of treatment, compared to a reduction of 0.5% from baseline of 8.37% for placebo. Only 45.4% of dorzagliatin patients met the American Diabetes Association's treatment goal of HbA1c < 7%, whereas only 21.5% of placebo patients could. Furthermore, less than 1% of dorzagliatin patients had hypoglycemia during the study period.

Headquarters: No.2, Lane 36, Xuelin Road, Pudong District, Shanghai

CEO: Li Chen

Founded: 2011

Website: https://www.huamedicine.com/En